SparingVision: Funding, Investors & Team (Sep 2026)
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.
SparingVision has raised $119M across 2 funding rounds on record, the most recent a Series B of $74.9M announced in Sep 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
SparingVision Company Profile and Key Stats
Latest funding round on record: Sep 2022.
SparingVision Funding Rounds
SparingVision raised $44.5M in an undisclosed round announced in Oct 2020.
1.9 years later, a Series B of $74.9M was announced in Sep 2022.
SparingVision Founders and Leadership Team
No contact details are on record for this team yet.
SparingVision Funding Compared to Other Biotechnology Startups
SparingVision's latest round of $74.9M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like SparingVision in Biotechnology and Paris
Companies Similar to SparingVision
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
SparingVision Funding FAQs
What does SparingVision do?
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.
How much funding has SparingVision raised?
SparingVision has raised $119M across 2 rounds on record. The most recent is a Series B of $74.9M announced in Sep 2022.
When did SparingVision last raise funding?
SparingVision's most recent funding round on record is a Series B of $74.9M, announced in Sep 2022.
Who founded SparingVision?
FundedIQ lists Jose Alain Sahel (Founder) at SparingVision.
Who is the CEO of SparingVision?
Stephane Boissel is listed as CEO at SparingVision.
Where is SparingVision headquartered?
SparingVision is based in Paris, Ile-De-France, France.
How many employees does SparingVision have?
SparingVision is in the 11-50 employee band.
How does SparingVision's funding compare to other Biotechnology startups?
SparingVision's latest round of $74.9M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's SparingVision Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for SparingVision is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.